Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 May;36(5):938–941. doi: 10.1128/aac.36.5.938

Excretion of cefprozil into human breast milk.

W C Shyu 1, V R Shah 1, D A Campbell 1, J Venitz 1, V Jaganathan 1, K A Pittman 1, R B Wilber 1, R H Barbhaiya 1
PMCID: PMC188771  PMID: 1510416

Abstract

The excretion of cefprozil into breast milk in nine healthy, lactating female subjects was investigated. Each subject received a single 1,000-mg oral dose of cefprozil consisting of cis and trans isomers in an approximately 90:10 ratio. Serial blood, urine, and breast milk samples were collected and analyzed for the concentrations of the cis and trans isomers by a specific high-pressure liquid chromatography-UV assay. The mean pharmacokinetic parameters for both isomers were essentially the same. The mean peak concentrations in plasma for the cis isomer were 14.8 micrograms/ml, and the area under the concentration curve was 54.8 micrograms.h/ml. The mean values of elimination half-life, renal clearance, and urinary excretion for the cis isomer were 1.69 h, 164 ml/min, and 60%, respectively. The mean concentrations in milk of the cis isomer over a 24-h period ranged from 0.25 to 3.36 micrograms/ml, with the maximum concentration appearing at 6 h after dosing. The average maximum concentration in milk of the trans isomer was less than 0.26 micrograms/ml. The concentrations of the trans isomer in plasma and in breast milk were about 1/10 of those for the cis isomer. Less than 0.3% of the dose was excreted in breast milk for both isomers of cefprozil. Even if one assumes that the concentration of cefprozil in milk remains constant at 3.36 micrograms/ml (the highest concentration of cefprozil observed in breast milk), an infant ingesting an average of 800 ml of milk per day will be exposed to a maximum amount of about 3 mg of cefprozil per day. This value represents about 0.3% of the maternal dose. Low excretion of cefprozil in breast milk and the excellent safety profile of cefprozil suggest that this cephalosporin may be administered to nursing mothers when indicated.

Full text

PDF
938

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbhaiya R. H., Gleason C. R., Shyu W. C., Wilber R. B., Martin R. R., Pittman K. A. Phase I study of single-dose BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):202–205. doi: 10.1128/aac.34.2.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbhaiya R. H., Shukla U. A., Gleason C. R., Shyu W. C., Pittman K. A. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother. 1990 Jun;34(6):1210–1213. doi: 10.1128/aac.34.6.1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barbhaiya R. H., Shukla U. A., Gleason C. R., Shyu W. C., Wilber R. B., Martin R. R., Pittman K. A. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother. 1990 Jun;34(6):1198–1203. doi: 10.1128/aac.34.6.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Branebjerg P. E., Heisterberg L. Blood and milk concentrations of ampicillin in mothers treated with pivampicillin and in their infants. J Perinat Med. 1987;15(6):555–558. doi: 10.1515/jpme.1987.15.6.555. [DOI] [PubMed] [Google Scholar]
  5. Chin N. X., Neu H. C. Comparative antibacterial activity of a new oral cephalosporin, BMY-28100. Antimicrob Agents Chemother. 1987 Mar;31(3):480–483. doi: 10.1128/aac.31.3.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cho N., Fukunaga K., Kunii K. [Pharmacokinetic studies on cefsulodin in perinatal period]. Jpn J Antibiot. 1989 Dec;42(12):2735–2742. [PubMed] [Google Scholar]
  7. Dubois M., Delapierre D., Chanteux L., Demonty J., Lambotte R., Kramp R., Dresse A. A study of the transplacental transfer and the mammary excretion of cefoxitin in humans. J Clin Pharmacol. 1981 Nov-Dec;21(11-12):477–483. doi: 10.1002/j.1552-4604.1981.tb05653.x. [DOI] [PubMed] [Google Scholar]
  8. Eliopoulos G. M., Reiszner E., Wennersten C., Moellering R. C., Jr In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Apr;31(4):653–656. doi: 10.1128/aac.31.4.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kafetzis D. A., Brater D. C., Fanourgakis J. E., Voyatzis J., Georgakopoulos P. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. Antimicrob Agents Chemother. 1983 Jun;23(6):870–873. doi: 10.1128/aac.23.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kafetzis D. A., Siafas C. A., Georgakopoulos P. A., Papadatos C. J. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981;70(3):285–288. doi: 10.1111/j.1651-2227.1981.tb16553.x. [DOI] [PubMed] [Google Scholar]
  11. Leitner F., Pursiano T. A., Buck R. E., Tsai Y. H., Chisholm D. R., Misiek M., Desiderio J. V., Kessler R. E. BMY 28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Feb;31(2):238–243. doi: 10.1128/aac.31.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Matheson I., Samseth M., Sande H. A. Ampicillin in breast milk during puerperal infections. Eur J Clin Pharmacol. 1988;34(6):657–659. doi: 10.1007/BF00615235. [DOI] [PubMed] [Google Scholar]
  13. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57–60. [PubMed] [Google Scholar]
  14. Riegelman S., Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980 Oct;8(5):509–534. doi: 10.1007/BF01059549. [DOI] [PubMed] [Google Scholar]
  15. Scribner R. K., Marks M. I., Finkhouse B. D. In vitro activity of BMY-28100 against common isolates from pediatric infections. Antimicrob Agents Chemother. 1987 Apr;31(4):630–631. doi: 10.1128/aac.31.4.630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shyu W. C., Pittman K. A., Wilber R. B., Matzke G. R., Barbhaiya R. H. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol. 1991 Apr;31(4):362–371. doi: 10.1002/j.1552-4604.1991.tb03719.x. [DOI] [PubMed] [Google Scholar]
  17. Shyu W. C., Shukla U. A., Shah V. R., Papp E. A., Barbhaiya R. H. Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study. Pharm Res. 1991 Aug;8(8):992–996. doi: 10.1023/a:1015896722170. [DOI] [PubMed] [Google Scholar]
  18. Shyu W. C., Wilber R. B., Pittman K. A., Garg D. C., Barbhaiya R. H. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment. J Clin Pharmacol. 1991 Apr;31(4):372–376. doi: 10.1002/j.1552-4604.1991.tb03720.x. [DOI] [PubMed] [Google Scholar]
  19. Wilson J. T., Brown R. D., Hinson J. L., Dailey J. W. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu Rev Pharmacol Toxicol. 1985;25:667–689. doi: 10.1146/annurev.pa.25.040185.003315. [DOI] [PubMed] [Google Scholar]
  20. Yoshioka H., Cho K., Takimoto M., Maruyama S., Shimizu T. Transfer of cefazolin into human milk. J Pediatr. 1979 Jan;94(1):151–152. doi: 10.1016/s0022-3476(79)80384-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES